folic acid Side Effects
Also known as: Folvite
Analysis of 241,433 adverse event reports submitted to the FDA from 2003 to 2025.
Total Reports
241,433
Death-Related
22,144
9.2% of reports
Hospitalizations
87,188
36.1% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 22,144 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 5,981 |
| PNEUMONIA | 2,632 |
| OFF LABEL USE | 2,622 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 2,540 |
| FATIGUE | 2,504 |
| DIARRHOEA | 2,332 |
| VOMITING | 2,210 |
| DYSPNOEA | 2,194 |
| RHEUMATOID ARTHRITIS | 2,150 |
| RASH | 2,134 |
| HYPERTENSION | 2,133 |
| SYSTEMIC LUPUS ERYTHEMATOSUS | 2,117 |
| TYPE 2 DIABETES MELLITUS | 2,082 |
| PAIN | 2,077 |
| HYPOAESTHESIA | 2,027 |
| GLOSSODYNIA | 2,014 |
| INFUSION RELATED REACTION | 2,006 |
| DUODENAL ULCER PERFORATION | 1,998 |
| ARTHRALGIA | 1,997 |
| FIBROMYALGIA | 1,992 |
Reactions in Hospitalization Reports
Top reactions in 87,188 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| FATIGUE | 7,987 |
| PNEUMONIA | 7,501 |
| PAIN | 7,490 |
| DYSPNOEA | 7,236 |
| ARTHRALGIA | 6,934 |
| DIARRHOEA | 6,899 |
| OFF LABEL USE | 6,816 |
| NAUSEA | 6,613 |
| PYREXIA | 6,481 |
| DRUG INEFFECTIVE | 6,171 |
| VOMITING | 6,128 |
| FALL | 5,610 |
| RHEUMATOID ARTHRITIS | 5,556 |
| HEADACHE | 5,140 |
| ASTHENIA | 5,132 |
| RASH | 5,102 |
| CONDITION AGGRAVATED | 4,886 |
| MALAISE | 4,867 |
| DIZZINESS | 4,620 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 4,163 |
Nearby — Related Medications
What the FAERS Data Reveals About folic acid Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 241,433 voluntary reports linked to folic acid and its brand equivalents (Folvite), spanning 2003 through 2025. Of those, 22,144 (9.2%) listed death as an outcome and 87,188 (36.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 68% were female and 32% male; age distribution skews toward 45-64, with 61,818 reports in that bracket. The single most reported reaction is drug ineffective with 24,765 submissions, followed by fatigue and pain.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.